[Translation] A post-marketing clinical trial to evaluate the efficacy and safety of beraprost sodium extended-release tablets in patients with idiopathic pulmonary arterial hypertension (IPAH), hereditary pulmonary arterial hypertension (HPAH), and connective tissue disease-related pulmonary arterial hypertension (CTD-PAH) using placebo as control
主要目的:以安慰剂为对照,分析治疗开始后16周与基线比较,6分钟步行距离(6MWD)的变化情况,评价贝前列素钠缓释片治疗WHO心功能分级Ⅰ-Ⅲ级的IPAH、HPAH以及CTD-PAH患者的有效性。
[Translation] Main objective: Using placebo as control, analyze the changes in 6-minute walk distance (6MWD) 16 weeks after the start of treatment compared with baseline, and evaluate the effectiveness of beraprost sodium sustained-release tablets in the treatment of IPAH, HPAH and CTD-PAH patients with WHO cardiac function grade Ⅰ-Ⅲ.